{"id":5047,"date":"2024-01-30T01:42:00","date_gmt":"2024-01-30T01:42:00","guid":{"rendered":"https:\/\/economicherald.net\/?p=5047"},"modified":"2024-01-30T01:42:00","modified_gmt":"2024-01-30T01:42:00","slug":"asx-health-stocks-a-breakthrough-for-car-t-therapy-arovella-signs-deal-to-advance-car-inkt-platform","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=5047","title":{"rendered":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform"},"content":{"rendered":"

Arovella enters into a licensing deal with UNC Lineberger
\nThe deal will see IL-12-TM used in Arovella\u2019s CAR-iNKT cell platform
\nInvion jumps 25pc after quarterly update<\/p>\n

\u00a0<\/p>\n

Arovella signs licence deal in US<\/h2>\n

Arovella Therapeutics (ASX:ALA)<\/a><\/strong> has entered into a global, exclusive licence with University of North Carolina Lineberger Comprehensive Cancer Center<\/strong> to incorporate the novel armouring cytokine technology (IL-12-TM)<\/strong> for its CAR-iNKT cell platform<\/strong>.<\/p>\n

IL-12-TM is a modified version of the human cytokine, interleukin 12 (IL-12), which is considered the ideal candidate for human tumour immunotherapy.<\/p>\n

However, side effects associated with IL-12 \u00a0have limited its use as a standalone therapeutic.<\/p>\n

The UNC Lineberger has worked on modifying IL-12-TM to include a \u2018membrane anchor\u2019, which keeps the IL-12 attached to the CARiNKT cell, and prevents it from circulating freely in the patient\u2019s bloodstream.<\/p>\n

This enables the IL-12-TM to have the desired effect on the CAR-iNKT cell, and reduces the risk of off-target effects and toxicity.<\/p>\n

The technology was developed by Professor Gianpietro Dotti<\/strong>, a pioneer of CARiNKT cells, and was recently published in the prestigious peer-reviewed journal Nature Communications<\/em>.<\/p>\n

When the IL-12-TM technology was tested on mice with neuroblastoma, and the mice were assessed four weeks after dosing, investigators found that CAR-iNKT cells containing IL-12-TM were at much higher numbers in the bloodstream (>10 times) than CAR-iNKT cells that did not contain IL-12.<\/p>\n

Investigators also found that approximately 75% of the mice were still alive 60 days after treatment for the IL-12-TM group, while all mice in the group treated with CAR-iNKT cells lacking IL-12 had died.<\/p>\n

Arovella says the licence agreement announced today has no immediate material financial impact on the company.<\/p>\n

In addition to this study, Arovella continues to work with Imugene (ASX:IMU)<\/a>, combing its oncolytic virus platform, CF33, with Arovella\u2019s ALA101 drug.<\/p>\n

The company believes incorporating IL-12-TM may provide improved activity against a range of solid tumours for this collaboration.<\/p>\n

\u00a0<\/p>\n

Invion awaits HREC approval for Phase 1\/2 trial<\/h2>\n

Invion (ASX:IVX)<\/a><\/strong> meanwhile jumped 25% this morning reporting its quarterly activities.<\/p>\n

During the quarter, Invion said that it completed lodgement of the Phase I\/II nonmelanoma skin cancer (NMSC)<\/strong> trial application with the Human Research Ethics Committee (HREC).<\/strong><\/p>\n

First patient recruitment is expected in the coming months (subject to HREC approval).<\/p>\n

In the trial, Invion said it will be using an adaptive trial design for greater flexibility to incorporate dose optimisation and efficacy signal endpoints, on top of the usual safety data.<\/p>\n

Separately, in the oral antimicrobial space, Invion is focusing on periodontal diseases, which it says represents a significant unmet need.<\/p>\n

<\/span><\/p>\n

The post ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform<\/a> appeared first on Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"

Arovella enters into a licensing deal with UNC Lineberger The deal will see IL-12-TM used in Arovella\u2019s CAR-iNKT cell platform Invion jumps 25pc after quarterly [more…]<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-5047","post","type-post","status-publish","format-standard","hentry","category-finance"],"yoast_head":"\nASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=5047\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Arovella enters into a licensing deal with UNC Lineberger The deal will see IL-12-TM used in Arovella\u2019s CAR-iNKT cell platform Invion jumps 25pc after quarterly [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=5047\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-30T01:42:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform\",\"datePublished\":\"2024-01-30T01:42:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047\"},\"wordCount\":470,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5047#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=5047\",\"name\":\"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"datePublished\":\"2024-01-30T01:42:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=5047\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=5047#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=5047","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald","og_description":"Arovella enters into a licensing deal with UNC Lineberger The deal will see IL-12-TM used in Arovella\u2019s CAR-iNKT cell platform Invion jumps 25pc after quarterly [more...]","og_url":"https:\/\/economicherald.net\/?p=5047","og_site_name":"Economic Herald","article_published_time":"2024-01-30T01:42:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=5047#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=5047"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform","datePublished":"2024-01-30T01:42:00+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=5047"},"wordCount":470,"commentCount":0,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"articleSection":["Finance"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/economicherald.net\/?p=5047#respond"]}]},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=5047","url":"https:\/\/economicherald.net\/?p=5047","name":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"datePublished":"2024-01-30T01:42:00+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=5047#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=5047"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=5047#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: A breakthrough for CAR T therapy? Arovella signs deal to advance CAR-iNKT platform"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5047"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/5047\/revisions"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}